PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17390169-7 2007 As a parameter for angiogenic activity, vascular endothelial growth factor (VEGF) secretion was measured, revealing reduced VEGF concentrations under Suramin treatment in both cell culture medium and ascites. Suramin 150-157 vascular endothelial growth factor A Homo sapiens 40-74 25168661-7 2014 Moreover, suramin suppressed angiogenesis and expression of vascular endothelial growth factor, a molecule associated with angiogenesis in the injured peritoneum. Suramin 10-17 vascular endothelial growth factor A Homo sapiens 60-94 22521862-6 2012 RESULTS: Addition of 20:3n-9 and n-3 eicosatrienoic acid (20:3n-3) dose dependently inhibited VEGF-A-stimulated angiogenesis (more than the positive control suramin). Suramin 157-164 vascular endothelial growth factor A Homo sapiens 94-100 19219548-6 2009 Herein, we show that in human endothelial cells, VEGF-induced angiogenesis is mitigated by dimethylsphingosine and suramin; inhibitors of sphingosine kinase 1(SphK-1) and sphingosine1-phosphate receptor 1(S1P (1)), respectively, and this were bypassed by LacCer but not by S1P. Suramin 115-122 vascular endothelial growth factor A Homo sapiens 49-53 17390169-7 2007 As a parameter for angiogenic activity, vascular endothelial growth factor (VEGF) secretion was measured, revealing reduced VEGF concentrations under Suramin treatment in both cell culture medium and ascites. Suramin 150-157 vascular endothelial growth factor A Homo sapiens 76-80 17390169-7 2007 As a parameter for angiogenic activity, vascular endothelial growth factor (VEGF) secretion was measured, revealing reduced VEGF concentrations under Suramin treatment in both cell culture medium and ascites. Suramin 150-157 vascular endothelial growth factor A Homo sapiens 124-128 8841939-0 1996 Suramin is a potent inhibitor of vascular endothelial growth factor. Suramin 0-7 vascular endothelial growth factor A Homo sapiens 33-67 16701826-7 2005 The binding affinity of the peptide for VEGF(165) was ascertained by surface plasmon resonance and compared with the heparin mimic suramin; the peptide binds to VEGF(165) 100-fold stronger than the sulfonated compound. Suramin 131-138 vascular endothelial growth factor A Homo sapiens 161-165 15928663-9 2005 Urinary VEGF was affected by Suramin at doses above 50 mg ml(-1), corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. Suramin 29-36 vascular endothelial growth factor A Homo sapiens 8-12 15928663-9 2005 Urinary VEGF was affected by Suramin at doses above 50 mg ml(-1), corresponding to the estimated threshold of saturation of Suramin binding to urine albumin. Suramin 124-131 vascular endothelial growth factor A Homo sapiens 8-12 8841939-4 1996 We have tested the hypothesis, whether the antiangiogenic effect of suramin may be mediated via inhibition of VEGF function. Suramin 68-75 vascular endothelial growth factor A Homo sapiens 110-114 8841939-5 1996 Using cultured endothelial cells and a [3H]thymidine incorporation assay we were able to show, that the action of VEGF upon mitogenicity is inhibited by suramin in a dose-dependent manner. Suramin 153-160 vascular endothelial growth factor A Homo sapiens 114-118 8841939-7 1996 Suramin inhibited VEGF-inducible tyrosine phosphorylation of KDR as determined by in vitro kinase assay. Suramin 0-7 vascular endothelial growth factor A Homo sapiens 18-22 8841939-8 1996 Moreover, suramin was shown to inhibit VEGF-induced tyrosine phosphorylation of KDR in intact cells, indicating an interaction of suramin with the VEGF-receptor KDR as the cause of its inhibitory activity. Suramin 10-17 vascular endothelial growth factor A Homo sapiens 39-43 8841939-8 1996 Moreover, suramin was shown to inhibit VEGF-induced tyrosine phosphorylation of KDR in intact cells, indicating an interaction of suramin with the VEGF-receptor KDR as the cause of its inhibitory activity. Suramin 10-17 vascular endothelial growth factor A Homo sapiens 147-151 8841939-8 1996 Moreover, suramin was shown to inhibit VEGF-induced tyrosine phosphorylation of KDR in intact cells, indicating an interaction of suramin with the VEGF-receptor KDR as the cause of its inhibitory activity. Suramin 130-137 vascular endothelial growth factor A Homo sapiens 39-43 8841939-8 1996 Moreover, suramin was shown to inhibit VEGF-induced tyrosine phosphorylation of KDR in intact cells, indicating an interaction of suramin with the VEGF-receptor KDR as the cause of its inhibitory activity. Suramin 130-137 vascular endothelial growth factor A Homo sapiens 147-151 8841939-9 1996 The antiangiogenic effect of suramin may be mediated-at least in part-by inhibition of VEGF function. Suramin 29-36 vascular endothelial growth factor A Homo sapiens 87-91 33396366-0 2020 Molecular Targeting of VEGF with a Suramin Fragment-DOCA Conjugate by Mimicking the Action of Low Molecular Weight Heparins. Suramin 35-42 vascular endothelial growth factor A Homo sapiens 23-27 1998521-4 1991 Guinea pig [125I]VPF binding to endothelial cells was inhibited by human VPF (ID50 = 0.8 ng/ml) and by suramin (ID50 = 75 micrograms/ml) but not by heparin. Suramin 103-110 vascular endothelial growth factor A Homo sapiens 17-20 1719003-9 1991 In contrast, suramin and protamin sulfate completely displaced 125I-VAS/VEGF binding from HUVE cells. Suramin 13-20 vascular endothelial growth factor A Homo sapiens 72-76 33396366-2 2020 In the present study, we developed a novel suramin fragment and deoxycholic acid conjugate (SFD) that exhibited the potential to bind to the heparin-binding site (HBD) of vascular endothelial growth factor (VEGF) and to inhibit its pathogenic action for the first time. Suramin 43-50 vascular endothelial growth factor A Homo sapiens 171-205 33396366-2 2020 In the present study, we developed a novel suramin fragment and deoxycholic acid conjugate (SFD) that exhibited the potential to bind to the heparin-binding site (HBD) of vascular endothelial growth factor (VEGF) and to inhibit its pathogenic action for the first time. Suramin 43-50 vascular endothelial growth factor A Homo sapiens 207-211